ArticleOPEN ACCESS

Calcitonin gene-related peptide (receptor) antibodies: An exciting avenue for migraine treatment

Genome Medicine
DOI: 10.1186/s13073-018-0524-7
12Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Specific prophylactic migraine treatments are urgently needed because of the unmet needs of many migraine patients. Antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor have recently shown efficacy in episodic and chronic migraine and will be available soon.

Cite

CITATION STYLE

APA

Maassen Van Den Brink, A., Terwindt, G. M., & van den Maagdenberg, A. M. J. M. (2018, February 22). Calcitonin gene-related peptide (receptor) antibodies: An exciting avenue for migraine treatment. Genome Medicine. BioMed Central Ltd. https://doi.org/10.1186/s13073-018-0524-7

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free